Australia markets closed

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
52.91-0.09 (-0.17%)
At close: 1:00PM EST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/03/2021
31/03/2020
31/03/2019
31/03/2018
Total revenue
567,592
548,970
644,769
669,893
661,913
Cost of revenue
277,727
252,314
245,044
224,169
198,405
Gross profit
289,865
296,656
399,725
445,724
463,508
Operating expenses
Research development
56,116
60,152
59,777
63,238
70,418
Selling general and administrative
92,692
91,355
93,413
89,971
88,196
Total operating expenses
148,808
151,507
153,190
149,531
158,614
Operating income or loss
141,057
145,149
246,535
296,193
304,894
Interest expense
3,039
1,363
725
256
304
Total other income/expenses net
-138,937
-556,396
17,856
27,119
-32,460
Income before tax
14,718
-391,073
298,035
356,854
292,368
Income tax expense
6,015
9,667
53,485
74,732
81,954
Income from continuing operations
8,703
-400,740
244,550
282,122
210,414
Net income
7,682
-386,653
244,241
281,777
211,150
Net income available to common shareholders
7,682
-386,653
244,241
281,777
211,150
Basic EPS
-
-10.12
6.35
7.23
5.26
Diluted EPS
-
-10.12
6.35
7.23
5.26
Basic average shares
-
38,210
38,460
38,990
40,155
Diluted average shares
-
38,210
38,460
38,990
40,155
EBITDA
-
-366,030
320,143
375,707
309,168